SIGRID Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health

Written By Brien L
Brien L
Previous

Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer
Next

SIGRID Raises USD 5 M to Accelerate Breakthrough Non-Systemic Metabolic Health Technology